On 24 Dec 2019, AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) spotted trading -44.25% off 52-week high price. On the other end, the stock has been noted 39.02% away from the low price over the last 52-weeks. The stock changed 3.64% to recent value of $2.28. The stock transacted 525664 shares during most recent day however it has an average volume of 957.94K shares. The company has 78.51M of outstanding shares and 70.97M shares were floated in the market.
AcelRx Pharmaceuticals, Inc. (ACRX) recently stated its third quarter 2019 financial results.
“Achieving 125 REMS-certified facilities two months ahead of our year-end goal demonstrates healthcare providers’ increasing interest in DSUVIA,” stated Vince Angotti, Chief Executive Officer of AcelRx. “We also expect to achieve our year-end objective of 125 formulary authorization s and anticipate expanded use across a variety of healthcare settings as the feedback on DSUVIA® from healthcare professionals continues to be very positive,” continued Angotti.
Financial Information
Cash, cash equivalents and short-term investments balance of $80.4M as of September 30, 2019;
Combined R&D and SG&A expenses for the third quarter of 2019 totaled $12.0M contrast to $8.8M for the third quarter of 2018. Not Including stock-based compensation expense, these amounts were $10.7M for the third quarter of 2019 contrast to $7.1M for the third quarter of 2018. R&D and SG&A expenses for the first nine months of 2019 totaled $35.8M contrast to $23.6M in the first nine months of 2018. Not Including stock-based compensation expense, these figures were $32.3M for the first nine months of 2019 contrast to $19.9M for the first nine months of 2018. The increase in R&D and SG&A expenses is primarily Because of increased personnel-related expenses for the commercial launch of DSUVIA. See the “Reconciliation of Non-GAAP Financial Measures” table below for a reconciliation of the non-GAAP operating expenses described above to their related GAAP measures;
Net cash outflow for the third quarter of 2019 was $11.1M, which included $0.6M in debt service;
For the third quarter of 2019, net loss was $12.7M, or $0.16 per basic and diluted share, contrast to $12.5M, or $0.21 per basic and diluted share, for the third quarter of 2018. Net loss for the first nine months of 2019 was $38.8M, or $0.49 per basic and diluted share, contrast to $34.6M, or $0.64 per basic and diluted share, for the previous year period.
The price moved ahead of 12.52% from the mean of 20 days, 13.86% from mean of 50 days SMA and performed -10.75% from mean of 200 days price. Company’s performance for the week was 1.79%, 37.35% for month and YTD performance remained -1.30%.
